Vaxil Bio Valuation
| VXL Stock | CAD 0.01 0.00 0.00% |
Vaxil Bio seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Vaxil Bio from inspecting the company fundamentals such as Price To Earning of (1.40) X, shares outstanding of 136.98 M, and Return On Equity of -0.2 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Vaxil Bio's valuation include:
Price Book 2.3892 | Enterprise Value 449.8 K | Enterprise Value Ebitda (2.28) |
Overvalued
Today
Please note that Vaxil Bio's price fluctuation is very steady at this time. Calculation of the real value of Vaxil Bio is based on 3 months time horizon. Increasing Vaxil Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vaxil stock is determined by what a typical buyer is willing to pay for full or partial control of Vaxil Bio. Since Vaxil Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vaxil Stock. However, Vaxil Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.01 | Real 0.0084 | Hype 0.01 |
The intrinsic value of Vaxil Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaxil Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaxil Bio helps investors to forecast how Vaxil stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaxil Bio more accurately as focusing exclusively on Vaxil Bio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Vaxil Bio's intrinsic value based on its ongoing forecasts of Vaxil Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Vaxil Bio's closest peers.
Vaxil Bio Cash |
|
Vaxil Valuation Trend
Analysing the historical paterns of Vaxil Bio's enterprise value and its market capitalization is a good way to estimate and gauge the value of Vaxil Bio over time and is usually enough for investors to make rational market timing decisions.
Vaxil Bio Total Value Analysis
Vaxil Bio is at this time estimated to have takeover price of 449.79 K with market capitalization of 1.37 M, debt of 85 K, and cash on hands of 307 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Vaxil Bio fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
449.79 K | 1.37 M | 85 K | 307 K |
Vaxil Bio Asset Utilization
One of the ways to look at asset utilization of Vaxil is to check how much profit was generated for every dollar of assets it reports. Vaxil Bio has a negative utilization of assets of -0.1 %, losing C$0.001018 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Vaxil Bio shows how discouraging it operates for each dollar spent on its assets.Vaxil Bio Ownership Allocation
Vaxil Bio shows a total of 136.98 Million outstanding shares. Vaxil Bio has 8.16 % of its outstanding shares held by insiders and 0.01 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vaxil Bio Profitability Analysis
Net Loss for the year was (254 K) with profit before overhead, payroll, taxes, and interest of 0.About Vaxil Bio Valuation
Our relative valuation model uses a comparative analysis of Vaxil Bio. We calculate exposure to Vaxil Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaxil Bio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.3 K | -2.4 K |
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.